jilodig.blogg.se - september 2023

Refer appropriately to prevent further deterioration (‘P’) X2.2.4 Combined systemic corticosteroids and antibiotics for treatment of exacerbation.X2.2.3 Antibiotics for treatment of exacerbations.X2.2.2 Systemic corticosteroids for treatment of exacerbations.X2.2.1 Inhaled bronchodilators for treatment of exacerbations.X2.1 Confirm exacerbation and categorise severity.D1.7 Clinical psychologist/psychiatrist.D1.3 GP practice nurse/ nurse practitioner/ respiratory educator/ respiratory nurse.P11 Long-term home non-invasive ventilation.Humidification therapy and nasal high flow (NHF) therapy P2.3 Haemophilus influenzae immunisation.P1.2.5 Electronic cigarettes (e-cigarettes).P1.2.2 Nicotine Receptor Partial Agonists.O10.3 Palliative oxygen therapy for dyspnoea.O9.2 Lung volume reduction surgery and bronchoscopic interventions.O8.1 Treatment of hypoxaemia and pulmonary hypertension.O7.13 Testosterone deficiencies and supplementation.O7.11 Combined Pulmonary Fibrosis and Emphysema.O7.8 Gastro-oesophageal reflux disease (GORD).O7.2.5 Coronary revascularisation procedures.O7.1 Increased risks from comorbidities in the presence of COPD.O6.8 Chest physiotherapy (Airway clearance techniques).

O6.5 Physical activity and sedentary behaviour.O6.4 Neuromuscular Electrical Stimulation.O4.2.1 Eosinophil count and inhaled corticosteroids.

O4.2 Inhaled corticosteroids and long-acting beta2-agonists and long-acting antimuscarinics in combination.

O4.1 Inhaled corticosteroids and long-acting beta2-agonists in combination (ICS/LABA).

O3.3 Inhaled corticosteroids versus long-acting beta2-agonists.

O2.2 Phosphodiesterase type-4 inhibitors.

O1.3 Assessment of response and continuation of bronchodilator therapy.

O1.2.3 Long-acting bronchodilator combinations (LAMA/LABA).

O1.2.2 Long-acting beta2-agonists (LABA).

O1.2.1 Long-acting muscarinic antagonists (LAMA).

O1.1.3 Short-acting bronchodilator combinations.

O1.1.2 Short-acting muscarinic antagonist (SAMA).

O1.1.1 Short-acting beta2-agonists (SABA).

C5.11 Electrocardiography and echocardiography.

C5.5 High resolution computed tomography.

Assessing acute response to bronchodilators

Key Recommendations of the COPD-X Guidelines.

COPD Guidelines Committee – Past and Present.

Summary of the Changes from the previous three versions of COPD-X.

Summary of the Changes – Version 2.68, October 2022.

The COPD-X Plan Version 2.68, October 2022.